Your browser doesn't support javascript.
loading
[Change of Neutrophils/ Lymphocyte Ratio in Patients with DLBCL before and after CHOP or R-CHOP Chemotherapy and Its Effect on Survival of Patients].
Li, Jing-Dong; Han, Xiao-Lin; Yang, Cui; Sun, Ling.
Afiliação
  • Li JD; Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang 453100, Henan Province, China.
  • Han XL; Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang 453100, Henan Province, China.
  • Yang C; Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang 453100, Henan Province, China.
  • Sun L; Department of Hematology; The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail: ljdoc2004@126.com.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 26(1): 182-186, 2018 Feb.
Article em Zh | MEDLINE | ID: mdl-29397840
ABSTRACT

OBJECTIVE:

To analyze the change of neutrophil/lymphocyte ratio (NLR) in patients with diffuse large B cell lymphoma (DLBCL) patients before and after CHOP or R-CHOP chemotherapy and its effect on survival of patients.

METHODS:

Clinical data of 60 patients with DLBCL were collected and were retrospectively analyzed. According to median NLR, 60 patients were divided into the group L in 33 cases (NLR< 2.27) and group H in 27 cases (NLR≥ 2.27). The curative effect and survival rate by using CHOP or R-CHOP after chemotherapy were compared between the two groups.

RESULTS:

In the group H, the total effective rate after chemotherapy (55.56%) was significantly lower than that of group L (87.88%), which showed that the difference were statistically significant (P<0.05); the cumulative survival rate of 1,2,3 years in the group H (70.37%, 59.26%, 37.04%) were significantly lower than that in the group L (93.94%, 87.88%, 60.61%) (P<0.05). The NLR≥ 2.27 before chemotherapy was the factor influencing the prognosis of patients with DLBCL (P<0.05).

CONCLUSION:

The NLR≥ 2.27 before chemotherapy may be used as a factor influencing the prognosis of patients with DLBCL, and the high NLR may indicate poor clinical efficacy and worse prognosis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: Zh Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: Zh Ano de publicação: 2018 Tipo de documento: Article